Sarcoma vaccine - MabVax/MSKCCAlternative Names: MV-Sarc
Latest Information Update: 16 Jun 2015
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
- Class Cancer vaccines; Monoclonal antibodies; Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Sarcoma